This content is machine translated An emerging interface with clinical relevance Lung cancer and neuroscience Lung cancer is still the leading cause of cancer-related mortality worldwide. In addition to established risk factors such as tobacco consumption and molecular alterations, the interaction between tumors and the...…
View Post 3 min This content is machine translated Precision therapy Targeted MET inhibition after progression with osimertinib Despite the success of osimertinib, a third-generation EGFR-TKI, in first-line therapy, the treatment of NSCLC after progression remains a challenge. SAVANNAH and ORCHARD have investigated the targeted addition of additional...…
View Post 3 min This content is machine translated De-escalation strategies De-escalation strategies – less is more Drug de-escalation is primarily driven by the need to spare patients unnecessary toxicity and the associated side effects and repeated hospital visits. However, de-escalation strategies may also have the potential...…
View Post 0 min This content is machine translated Advanced NSCLC MARIPOSA: Combination therapy as the new standard of care for EGFR-mutated NSCLC ... Dieser Inhalt ist nur für Benutzer der Gruppe: Medizinische Fachperson zugänglich Jetzt beitretenAlready a member? Log in here
View Post 3 min This content is machine translated Small cell lung carcinoma Durvalumab approved as first immunotherapy for patients with LS-SCLC Durvalumab has been approved as a monotherapy in Switzerland for the treatment of adult patients with unresectable small cell lung cancer (LS-SCLC, limited-stage small cell lung cancer) whose disease has...…
View Post 3 min This content is machine translated Non-small cell lung cancer Management of locally advanced NSCLC – where are we heading? Lung cancer is the second most common and deadliest type of cancer worldwide. Clinically, non-small cell lung cancer (NSCLC) is the most common pathologic form of lung cancer; approximately one-third…
View Post 5 min This content is machine translated Lung cancer Perioperative therapy for better efficacy Neoadjuvant or adjuvant immunotherapy can improve outcomes in patients with resectable non-small cell lung cancer (NSCLC). It has now been observed that perioperative therapies can combine the benefits of both…
View Post 8 min This content is machine translated Lung cancer An overview of non-small cell lung cancer across all stages The European Lung Cancer Congress is a joint project of major multidisciplinary societies representing thoracic oncology specialists working together to advance science, disseminate education and improve the practice of lung…
View Post 6 min This content is machine translated Non-small cell lung cancer Risk-adapted screening and treatment management Non-small cell lung carcinomas are the most common malignant tumors of the lung. 70–80% of all lung tumors can be assigned to this histology. A distinction can now be made…
View Post 2 min This content is machine translated Schwartz-Bartter syndrome Disruption of osmoregulation – effectively balancing electrolytes Schwartz-Bartter syndrome is characterized by an accumulation of water in the body, triggered by an increased release of ADH or ADH-like substances. Nausea, vomiting, headaches and muscle cramps can be…
View Post 4 min This content is machine translated Lung cancer Focus topics: Brain metastases, therapy response and PD-L1 expression Therapy management for lung cancer is entering a new era. The progress made is remarkable and sheds new light on the importance of tumor tests in diagnosis. Many insights have…
